Founded in 2009, Otologic Pharmaceutics, Inc. is committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders. Their lead program, HPN1010, is an oral medication that will enter clinical trials in collaboration with Oblato. The company's preclinical programs focus on the regeneration of auditory sensory epithelia lost as a result of age-related hearing loss or chronic NIHL, which has demonstrated restoration of auditory function in animal models of acute and chronic hearing loss. OPI's clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants has secondary indications in Meniere's Disease and tinnitus. Currently, no pharmacological treatment for hearing loss is available.